NewEdge Advisors’s AYTU BioPharma AYTU Stock Holding History

NewEdge Advisors’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-21	Closed	-$57	–	4197
2026 Q1	$57	Hold	21	–	–	﹤0.01%	4097
2025 Q4	$55	Hold	21	–	–	﹤0.01%	4168
2025 Q3	$39	Hold	21	–	–	﹤0.01%	4057
2025 Q2	$46	Hold	21	–	–	﹤0.01%	3931
2025 Q1	$25	Hold	21	–	–	﹤0.01%	3881
2024 Q4	$36	Hold	21	–	–	﹤0.01%	3828
2024 Q3	$49	Hold	21	–	–	﹤0.01%	3748
2024 Q2	$61	Hold	21	–	–	﹤0.01%	3708
2024 Q1	$64	Hold	21	–	–	﹤0.01%	3717
2023 Q4	$60	Hold	21	–	–	﹤0.01%	3660
2023 Q3	$57	Hold	21	–	–	﹤0.01%	3389
2023 Q2	$34	Hold	21	–	–	﹤0.01%	3446
2023 Q1	$47	Sell	21 -1	-5%	-$3	﹤0.01%	3364
2022 Q4	$0	Buy	+22	New	+$83	﹤0.01%	4088

Other funds holding AYTU

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Crown Advisors Management Larkspur, California $182M AUM 103.97% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

NewEdge Advisors's AYTU Position: Q2 2026 in Review

NewEdge Advisors sold out of AYTU BioPharma (AYTU) in Q2 2026, closing a stake of 21 shares — an estimated $57 sold.

NewEdge Advisors first reported a position in AYTU in Q4 2022 and held it in 14 quarters. The position peaked at $64 in Q1 2024. 38 funds tracked by Wall St. Rank hold AYTU as of Q2 2026.

NewEdge Advisors reported no remaining AYTU BioPharma position as of Q2 2026 after selling out during the quarter.
NewEdge Advisors sold 21 AYTU BioPharma shares in Q2 2026, an estimated $57.
NewEdge Advisors first reported a position in AYTU BioPharma in Q4 2022 and held it in 14 quarters.
NewEdge Advisors's AYTU BioPharma position peaked at $64 in Q1 2024.
38 funds tracked by Wall St. Rank held AYTU BioPharma as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.